Methods and compositions for reducing serum levels of immunoglobulin E (IgE)

US9289421B2 · kind B2 · utility

Assignee

• University of South Florida · US

Inventors

• Thomas KLEIN · Radolfzell, DE
• Catherine Newton · Sunrise, US
• Catherine Patterson · Dublin, IE
• Marisela Agudelo · Miami, US

Key dates

• Filing date: Aug 29, 2012
• Grant date: Mar 22, 2016
• Expiry date: Feb 3, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides methods and pharmaceutical compositions for reducing the serum level of immunoglobulin IgE in an animal or human subject. It has been found that reducing or inhibiting the activity of the cannabinoid receptor CB2 leads to an increase in IgE in serum levels. Conversely, activation of the CB2 receptor by an agonist results in a reduction in IgE serum levels. The compositions and methods of the disclosure, therefore, provide a means to reduce or eliminate symptoms of immune system-related conditions resulting from IgE generation, such as an allergy, hay fever, and the like.